Condition: Huntington Disease · Sponsor: Novartis Pharmaceuticals
The purpose is to assess safety and tolerability of votoplam and to determine whether votoplam slows disease progression in patients with early symptomatic Huntington's disease (HD) compared to the control arm. HTT227 - current compound code (former code is PTC518 from PTC Therapeutics), HTT227 is Novartis code under Novartis sponsorship.
This description comes directly from the study's public registry record.
Novartis Pharmaceuticals · 1-888-669-6682 · novartis.email@novartis.com
Novartis Pharmaceuticals · +41613241111
Always discuss trial participation with your own doctor first.
| University of CA San Diego | La Jolla, California, United States | Recruiting |
| CenExcel Rocky Mtn Clin Research | Englewood, Colorado, United States | Recruiting |
| Georgetown University | Washington D.C., District of Columbia, United States | Recruiting |
| University Of South Florida | Tampa, Florida, United States | Recruiting |
| Parkinsons-Movement Disorder Ctr | Chicago, Illinois, United States | Recruiting |
| Indiana University Health | Indianapolis, Indiana, United States | Recruiting |
| University of Iowa Health Care | Iowa City, Iowa, United States | Recruiting |
| University of Kansas Hospital | Fairway, Kansas, United States | Recruiting |
| Trinity Health Michigan | Grand Rapids, Michigan, United States | Recruiting |
| Albany Medical College | Albany, New York, United States | Recruiting |
| UBMD Neurology | Buffalo, New York, United States | Recruiting |
| Columbia University Irving Medical | New York, New York, United States | Recruiting |
+ 29 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07326709